JP2016528894A5 - - Google Patents

Download PDF

Info

Publication number
JP2016528894A5
JP2016528894A5 JP2016530062A JP2016530062A JP2016528894A5 JP 2016528894 A5 JP2016528894 A5 JP 2016528894A5 JP 2016530062 A JP2016530062 A JP 2016530062A JP 2016530062 A JP2016530062 A JP 2016530062A JP 2016528894 A5 JP2016528894 A5 JP 2016528894A5
Authority
JP
Japan
Prior art keywords
nucleic acid
stem cell
enzyme
guide rna
target dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016530062A
Other languages
English (en)
Other versions
JP2016528894A (ja
JP6739335B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/048140 external-priority patent/WO2015013583A2/en
Publication of JP2016528894A publication Critical patent/JP2016528894A/ja
Publication of JP2016528894A5 publication Critical patent/JP2016528894A5/ja
Application granted granted Critical
Publication of JP6739335B2 publication Critical patent/JP6739335B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (34)

  1. 標的DNAに相補的なガイドRNAと共局在複合体を形成し且つ部位特異的に前記標的DNAを切断するCas酵素、を含む幹細胞内で、前記標的DNAを改変する方法であって、前記方法は、
    記標的DNAに相補的であり前記Cas酵素を前記標的DNAまで誘導(guide)するガイドRNA、をコードする第1外来性核酸を、前記幹細胞に導入すること;ここで前記ガイドRNAおよび前記Cas酵素は前記標的DNAに対する共局在複合体のメンバーである、
    ドナー核酸配列を前記幹細胞に導入すること、
    を含み、
    前記ガイドRNAおよび前記Cas酵素が前記標的DNAに共局在し、前記Cas酵素が前記標的DNAを切断し、前記ドナー核酸配列が前記標的DNAに挿入されて前記幹細胞内で改変DNAを産生する、前記方法。
  2. 前記Cas酵素がCas9である、請求項1に記載の方法。
  3. 前記ガイドRNAが10ヌクレオチド〜500ヌクレオチドである、請求項1に記載の方法。
  4. 前記ガイドRNAが20ヌクレオチド〜100ヌクレオチドである、請求項1に記載の方法。
  5. 前記ガイドRNAがtracrRNA−crRNA融合体である、請求項1に記載の方法。
  6. 前記標的DNAがゲノムDNA、ミトコンドリアDNA、ウイルスDNA、または外来性DNAである、請求項1に記載の方法。
  7. 前記ドナー核酸配列が相同組換えにより挿入される、請求項1に記載の方法。
  8. 前記ドナー核酸配列が非相同末端結合により挿入される、請求項1に記載の方法。
  9. 前記Cas酵素または前記ガイドRNAが、前記幹細胞によって発現される外来性核酸として前記幹細胞に導入される、請求項1に記載の方法。
  10. 複数のドナー核酸および複数のガイドRNAを導入して、前記細胞内で前記標的DNAに複数の改変を生じさせることをさらに含む、請求項1に記載の方法。
  11. 幹細胞内で改変DNAを作製した後に前記Cas酵素をコードする核酸が、前記幹細胞のゲノムから除去される、請求項1に記載の方法。
  12. 前記ガイドRNAが、前記幹細胞の周囲の媒体から前記幹細胞内へと導入される、請求項1に記載の方法。
  13. 前記ガイドRNAが5’キャップ構造を含む、請求項12に記載の方法。
  14. 前記ガイドRNAがホスフェート基を欠く、請求項12に記載の方法。
  15. 前記ガイドRNAが前記幹細胞の周囲の媒体から連続的に供給される、請求項1に記載の方法。
  16. 前記幹細胞は、前記Cas酵素をコードする核酸を含み且つ酵素により除去可能なベクターまたはカセットを前記幹細胞のゲノムDNAに挿入することにより、遺伝的に改変されている、請求項1に記載の方法。
  17. 前記ベクターがPiggybacベクターである、請求項16に記載の方法。
  18. 前記Cas酵素をコードする核酸が、酵素を用いて除去される、請求項16に記載の方法。
  19. 前記Cas酵素をコードする核酸を含む前記酵素により除去可能なベクターまたはカセットは、酵素を用いて除去される、請求項16に記載の方法。
  20. 前記Cas酵素をコードする核酸を含む前記酵素により除去可能なベクターまたはカセットは、酵素を用いて挿入される、請求項16に記載の方法。
  21. 前記Cas酵素をコードする核酸を含む前記酵素により除去可能なベクターまたはカセットは、トランスポゼースを用いて除去される、請求項16に記載の方法。
  22. 前記Cas酵素をコードする核酸は誘導可能である、請求項16に記載の方法。
  23. 前記Cas酵素をコードする核酸は、ドキシサイクリン誘導性プロモータの影響下にある、請求項16に記載の方法。
  24. 前記Cas酵素をコードする核酸は、ドキシサイクリンを用いて誘導可能である、請求項16に記載の方法。
  25. 標的DNAに相補的なガイドRNAと共局在複合体を形成し且つ部位特異的に前記標的DNAを切断するCas酵素、をコードする第1外来性核酸を含む、幹細胞。
  26. 前記標的DNAに相補的であり前記Cas酵素を前記標的DNAまで誘導(guide)するガイドRNA、をコードする第2外来性核酸をさらに含み、前記ガイドRNAおよび前記Cas酵素が前記標的DNAに対する共局在複合体のメンバーである、請求項25に記載の幹細胞。
  27. ドナー核酸配列をコードする第3外来性核酸をさらに含む、請求項26に記載の幹細胞。
  28. 前記Cas酵素の発現を促進するための誘導性プロモーターをさらに含む請求項25に記載の幹細胞。
  29. 前記第1外来性核酸が前記細胞のゲノムDNAからトランスポゼースを使用して除去可能である、請求項25に記載の幹細胞。
  30. 前記Cas酵素がCas9である、請求項25に記載の幹細胞。
  31. 前記ガイドRNAが10ヌクレオチド〜500ヌクレオチドである、請求項25に記載の幹細胞。
  32. 前記ガイドRNAが20ヌクレオチド〜100ヌクレオチドである、請求項25に記載の幹細胞。
  33. 前記ガイドRNAがtracrRNA−crRNA融合体である、請求項25に記載の幹細胞。
  34. 前記標的DNAがゲノムDNA、ミトコンドリアDNA、ウイルスDNA、または外来性DNAである、請求項25に記載の幹細胞。
JP2016530062A 2013-07-26 2014-07-25 ゲノムエンジニアリング Active JP6739335B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361858866P 2013-07-26 2013-07-26
US61/858,866 2013-07-26
PCT/US2014/048140 WO2015013583A2 (en) 2013-07-26 2014-07-25 Genome engineering

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020028641A Division JP6993063B2 (ja) 2013-07-26 2020-02-21 ゲノムエンジニアリング

Publications (3)

Publication Number Publication Date
JP2016528894A JP2016528894A (ja) 2016-09-23
JP2016528894A5 true JP2016528894A5 (ja) 2017-07-20
JP6739335B2 JP6739335B2 (ja) 2020-08-12

Family

ID=52390824

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016530062A Active JP6739335B2 (ja) 2013-07-26 2014-07-25 ゲノムエンジニアリング
JP2020028641A Active JP6993063B2 (ja) 2013-07-26 2020-02-21 ゲノムエンジニアリング
JP2021198648A Active JP7419328B2 (ja) 2013-07-26 2021-12-07 ゲノムエンジニアリング
JP2024002064A Pending JP2024029218A (ja) 2013-07-26 2024-01-10 ゲノムエンジニアリング

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020028641A Active JP6993063B2 (ja) 2013-07-26 2020-02-21 ゲノムエンジニアリング
JP2021198648A Active JP7419328B2 (ja) 2013-07-26 2021-12-07 ゲノムエンジニアリング
JP2024002064A Pending JP2024029218A (ja) 2013-07-26 2024-01-10 ゲノムエンジニアリング

Country Status (14)

Country Link
US (4) US10563225B2 (ja)
EP (4) EP3024964B1 (ja)
JP (4) JP6739335B2 (ja)
KR (2) KR20230096134A (ja)
CN (3) CN105473773B (ja)
AU (4) AU2014293015B2 (ja)
BR (1) BR112016001721B1 (ja)
CA (1) CA2918540A1 (ja)
ES (1) ES2715666T3 (ja)
HK (1) HK1218940A1 (ja)
IL (2) IL243560B (ja)
RU (2) RU2688462C2 (ja)
SG (3) SG11201600217QA (ja)
WO (1) WO2015013583A2 (ja)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
SG11201406547YA (en) 2012-04-25 2014-11-27 Regeneron Pharma Nuclease-mediated targeting with large targeting vectors
IL308158A (en) 2012-12-17 2023-12-01 Harvard College RNA-guided human genome engineering
EP2981617B1 (en) 2013-04-04 2023-07-05 President and Fellows of Harvard College Therapeutic uses of genome editing with crispr/cas systems
DK2986729T3 (en) 2013-04-16 2018-10-29 Regeneron Pharma TARGETED MODIFICATION OF ROOT THROUGH
JP2016528890A (ja) 2013-07-09 2016-09-23 プレジデント アンド フェローズ オブ ハーバード カレッジ CRISPR/Cas系を用いるゲノム編集の治療用の使用
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
DE202014010413U1 (de) 2013-09-18 2015-12-08 Kymab Limited Zellen und Organismen
WO2015070083A1 (en) 2013-11-07 2015-05-14 Editas Medicine,Inc. CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS
RU2685914C1 (ru) 2013-12-11 2019-04-23 Регенерон Фармасьютикалс, Инк. Способы и композиции для направленной модификации генома
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
EP3690044B1 (en) 2014-02-11 2024-01-10 The Regents of the University of Colorado, a body corporate Crispr enabled multiplexed genome engineering
EP3114227B1 (en) 2014-03-05 2021-07-21 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
WO2015138510A1 (en) 2014-03-10 2015-09-17 Editas Medicine., Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
WO2015148863A2 (en) 2014-03-26 2015-10-01 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
WO2015191693A2 (en) * 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
EP3177718B1 (en) 2014-07-30 2022-03-16 President and Fellows of Harvard College Cas9 proteins including ligand-dependent inteins
MX2017004890A (es) 2014-10-15 2018-02-12 Regeneron Pharma Metodos y composiciones para la generación o el mantenimiento de células pluripotentes.
WO2016065364A1 (en) * 2014-10-24 2016-04-28 Life Technologies Corporation Compositions and methods for enhancing homologous recombination
WO2016073990A2 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
NZ731962A (en) 2014-11-21 2022-07-01 Regeneron Pharma Methods and compositions for targeted genetic modification using paired guide rnas
CN107250148B (zh) 2014-12-03 2021-04-16 安捷伦科技有限公司 具有化学修饰的指导rna
WO2016094679A1 (en) 2014-12-10 2016-06-16 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
EP3271461A1 (en) * 2015-03-20 2018-01-24 Danmarks Tekniske Universitet Crispr/cas9 based engineering of actinomycetal genomes
EP4019635A1 (en) * 2015-03-25 2022-06-29 Editas Medicine, Inc. Crispr/cas-related methods, compositions and components
KR102648489B1 (ko) 2015-04-06 2024-03-15 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
SG11201708653RA (en) 2015-04-24 2017-11-29 Editas Medicine Inc Evaluation of cas9 molecule/guide rna molecule complexes
JP7030522B2 (ja) * 2015-05-11 2022-03-07 エディタス・メディシン、インコーポレイテッド 幹細胞における遺伝子編集のための最適化crispr/cas9システムおよび方法
WO2016196887A1 (en) 2015-06-03 2016-12-08 Board Of Regents Of The University Of Nebraska Dna editing using single-stranded dna
CN116334142A (zh) 2015-06-09 2023-06-27 爱迪塔斯医药公司 用于改善移植的crispr/cas相关方法和组合物
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2016205749A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
CN109536474A (zh) 2015-06-18 2019-03-29 布罗德研究所有限公司 降低脱靶效应的crispr酶突变
US10166255B2 (en) 2015-07-31 2019-01-01 Regents Of The University Of Minnesota Intracellular genomic transplant and methods of therapy
WO2017040511A1 (en) 2015-08-31 2017-03-09 Agilent Technologies, Inc. Compounds and methods for crispr/cas-based genome editing by homologous recombination
US11667911B2 (en) 2015-09-24 2023-06-06 Editas Medicine, Inc. Use of exonucleases to improve CRISPR/CAS-mediated genome editing
EP3365356B1 (en) 2015-10-23 2023-06-28 President and Fellows of Harvard College Nucleobase editors and uses thereof
ES2953925T3 (es) * 2015-11-04 2023-11-17 Fate Therapeutics Inc Ingeniería genómica de células pluripotentes
KR101885901B1 (ko) * 2015-11-13 2018-08-07 기초과학연구원 5' 말단의 인산기가 제거된 rna를 포함하는 리보핵산단백질 전달용 조성물
WO2017087708A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
EP3383409A4 (en) * 2015-12-02 2019-10-02 The Regents of The University of California COMPOSITIONS AND METHODS FOR MODIFYING TARGET NUCLEIC ACID
US11441146B2 (en) * 2016-01-11 2022-09-13 Christiana Care Health Services, Inc. Compositions and methods for improving homogeneity of DNA generated using a CRISPR/Cas9 cleavage system
CN106957856B (zh) * 2016-01-12 2020-07-28 中国科学院广州生物医药与健康研究院 无毛模型猪的重构卵及其构建方法和模型猪的构建方法
WO2017165862A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
US11597924B2 (en) 2016-03-25 2023-03-07 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
WO2017180694A1 (en) 2016-04-13 2017-10-19 Editas Medicine, Inc. Cas9 fusion molecules gene editing systems, and methods of use thereof
CA3026112A1 (en) 2016-04-19 2017-10-26 The Broad Institute, Inc. Cpf1 complexes with reduced indel activity
WO2017184768A1 (en) 2016-04-19 2017-10-26 The Broad Institute Inc. Novel crispr enzymes and systems
KR20230038804A (ko) * 2016-04-29 2023-03-21 바스프 플랜트 사이언스 컴퍼니 게엠베하 표적 핵산의 변형을 위한 개선된 방법
WO2017207589A1 (en) * 2016-06-01 2017-12-07 Kws Saat Se Hybrid nucleic acid sequences for genome engineering
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
WO2017223538A1 (en) 2016-06-24 2017-12-28 The Regents Of The University Of Colorado, A Body Corporate Methods for generating barcoded combinatorial libraries
US11471462B2 (en) 2016-06-27 2022-10-18 The Broad Institute, Inc. Compositions and methods for detecting and treating diabetes
US11359234B2 (en) 2016-07-01 2022-06-14 Microsoft Technology Licensing, Llc Barcoding sequences for identification of gene expression
US20180004537A1 (en) * 2016-07-01 2018-01-04 Microsoft Technology Licensing, Llc Molecular State Machines
US11566263B2 (en) 2016-08-02 2023-01-31 Editas Medicine, Inc. Compositions and methods for treating CEP290 associated disease
GB2568182A (en) 2016-08-03 2019-05-08 Harvard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
EP3510151A4 (en) 2016-09-09 2020-04-15 The Board of Trustees of the Leland Stanford Junior University HIGH-THROUGHPUT PRECISION GENE EDITING
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
CN110520530A (zh) 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
KR20190089175A (ko) * 2016-11-18 2019-07-30 진에딧 인코포레이티드 표적 핵산 변형을 위한 조성물 및 방법
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US11530388B2 (en) * 2017-02-14 2022-12-20 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of engineering human induced pluripotent stem cells to produce liver tissue
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
EP3596217A1 (en) 2017-03-14 2020-01-22 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
EP3601562A1 (en) 2017-03-23 2020-02-05 President and Fellows of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US20210115407A1 (en) 2017-04-12 2021-04-22 The Broad Institute, Inc. Respiratory and sweat gland ionocytes
WO2018195486A1 (en) 2017-04-21 2018-10-25 The Broad Institute, Inc. Targeted delivery to beta cells
EP3615672A1 (en) 2017-04-28 2020-03-04 Editas Medicine, Inc. Methods and systems for analyzing guide rna molecules
WO2018204777A2 (en) 2017-05-05 2018-11-08 The Broad Institute, Inc. Methods for identification and modification of lncrna associated with target genotypes and phenotypes
EP3622070A2 (en) 2017-05-10 2020-03-18 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
AU2018279829B2 (en) 2017-06-09 2024-01-04 Editas Medicine, Inc. Engineered Cas9 nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
WO2019014564A1 (en) 2017-07-14 2019-01-17 Editas Medicine, Inc. SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
MX2020001178A (es) 2017-07-31 2020-09-25 Regeneron Pharma Celulas madre embrionarias de raton transgenico con cas y ratones y usos de los mismos.
EP3676376A2 (en) 2017-08-30 2020-07-08 President and Fellows of Harvard College High efficiency base editors comprising gam
CN111344403A (zh) * 2017-09-15 2020-06-26 利兰斯坦福初级大学董事会 遗传工程细胞的多元性产生和条形码编制
KR20200121782A (ko) 2017-10-16 2020-10-26 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
US11268092B2 (en) 2018-01-12 2022-03-08 GenEdit, Inc. Structure-engineered guide RNA
CN112272516B (zh) 2018-04-06 2023-05-30 儿童医疗中心有限公司 用于体细胞重新编程和调整印记的组合物和方法
GB2589246A (en) 2018-05-16 2021-05-26 Synthego Corp Methods and systems for guide RNA design and use
US20210246505A1 (en) * 2018-06-21 2021-08-12 Memorial Sloan Kettering Cancer Center Compositions & methods for monitoring dna repair
KR20210053898A (ko) 2018-07-31 2021-05-12 더 브로드 인스티튜트, 인코퍼레이티드 신규 crispr 효소 및 시스템
CA3121268A1 (en) 2018-12-10 2020-06-18 Amgen Inc. Mutated piggybac transposase
BR112021018606A2 (pt) 2019-03-19 2021-11-23 Harvard College Métodos e composições para editar sequências de nucleotídeos
CN115175996A (zh) 2019-09-20 2022-10-11 博德研究所 新颖vi型crispr酶和系统
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
DE112021002672T5 (de) 2020-05-08 2023-04-13 President And Fellows Of Harvard College Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
EP4232583A1 (en) 2020-10-21 2023-08-30 Massachusetts Institute of Technology Systems, methods, and compositions for site-specific genetic engineering using programmable addition via site-specific targeting elements (paste)
TW202233660A (zh) 2020-10-30 2022-09-01 美商安進公司 過表現胰島素樣生長因子受體突變體以調節igf補充
KR20240055811A (ko) 2021-09-10 2024-04-29 애질런트 테크놀로지스, 인크. 프라임 편집을 위한 화학적 변형을 갖는 가이드 rna
CA3237300A1 (en) 2021-11-01 2023-05-04 Tome Biosciences, Inc. Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
WO2023122764A1 (en) 2021-12-22 2023-06-29 Tome Biosciences, Inc. Co-delivery of a gene editor construct and a donor template
WO2023205744A1 (en) 2022-04-20 2023-10-26 Tome Biosciences, Inc. Programmable gene insertion compositions
WO2023225670A2 (en) 2022-05-20 2023-11-23 Tome Biosciences, Inc. Ex vivo programmable gene insertion
WO2024020587A2 (en) 2022-07-22 2024-01-25 Tome Biosciences, Inc. Pleiopluripotent stem cell programmable gene insertion

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6689558B2 (en) 2000-02-08 2004-02-10 Sangamo Biosciences, Inc. Cells for drug discovery
EP1280928B1 (en) * 2000-05-10 2016-11-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Resistance to acetohydroxyacid synthase-inhibiting herbicides
CA2474486C (en) 2002-01-23 2013-05-14 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
KR100766952B1 (ko) 2002-12-09 2007-10-17 주식회사 툴젠 조절성 징크 핑거 단백질
JP2007521823A (ja) 2004-02-13 2007-08-09 ノボザイムス アクティーゼルスカブ プロテアーゼ変異型
DE102005062662A1 (de) 2005-12-23 2007-06-28 Basf Ag Verfahren zur Herstellung optisch aktiver Alkohole
BRPI0808704B1 (pt) 2007-03-02 2022-01-18 Dupont Nutrition Biosciences Aps Método para gerar uma cultura inicial compreendendo pelo menos duas cepas variantes resistentes a bacteriófagos, cultura iniciadora e método de fermentação
US8546553B2 (en) 2008-07-25 2013-10-01 University Of Georgia Research Foundation, Inc. Prokaryotic RNAi-like system and methods of use
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
US9404098B2 (en) 2008-11-06 2016-08-02 University Of Georgia Research Foundation, Inc. Method for cleaving a target RNA using a Cas6 polypeptide
PH12012500097A1 (en) * 2009-07-21 2011-01-27 Shanghai Inst Organic Chem Potent small molecule inhibitors of autophagy, and methods of use thereof
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
NO332016B1 (no) 2009-12-29 2012-05-21 Stiftelsen Sintef Prøvebehandlingskassett og fremgangsmåte for å behandle og/eller analysere en prøve under sentrifugalkraft
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
MX336731B (es) * 2010-01-28 2016-01-28 Harvard College Composiciones y metodos para potenciar la actividad de proteasoma.
US10087431B2 (en) 2010-03-10 2018-10-02 The Regents Of The University Of California Methods of generating nucleic acid fragments
BR112012028805A2 (pt) 2010-05-10 2019-09-24 The Regents Of The Univ Of California E Nereus Pharmaceuticals Inc composições de endorribonuclease e métodos de uso das mesmas.
CN103025344B (zh) 2010-05-17 2016-06-29 桑格摩生物科学股份有限公司 新型dna-结合蛋白及其用途
US20140113376A1 (en) 2011-06-01 2014-04-24 Rotem Sorek Compositions and methods for downregulating prokaryotic genes
CA2841541C (en) 2011-07-25 2019-11-12 Sangamo Biosciences, Inc. Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
RU2650811C2 (ru) 2012-02-24 2018-04-17 Фред Хатчинсон Кэнсер Рисерч Сентер Композиции и способы лечения гемоглобинопатии
EP2820159B1 (en) 2012-02-29 2019-10-23 Sangamo Therapeutics, Inc. Methods and compositions for treating huntington's disease
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
ES2960803T3 (es) 2012-05-25 2024-03-06 Univ California Métodos y composiciones para la modificación de ADN diana dirigida por RNA y para la modulación de la transcripción dirigida por RNA
EP2880171B1 (en) 2012-08-03 2018-10-03 The Regents of The University of California Methods and compositions for controlling gene expression by rna processing
ES2926021T3 (es) 2012-10-23 2022-10-21 Toolgen Inc Composición para escindir un ADN objetivo que comprende un ARN guía específico para el ADN objetivo y ácido nucleico codificador de proteína Cas o proteína Cas, y uso de la misma
EP3617309A3 (en) 2012-12-06 2020-05-06 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
SG10201912328UA (en) 2012-12-12 2020-02-27 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
CN113355357A (zh) 2012-12-12 2021-09-07 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
AU2014235794A1 (en) 2013-03-14 2015-10-22 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US20140349400A1 (en) 2013-03-15 2014-11-27 Massachusetts Institute Of Technology Programmable Modification of DNA
EP2981617B1 (en) 2013-04-04 2023-07-05 President and Fellows of Harvard College Therapeutic uses of genome editing with crispr/cas systems
US20140349405A1 (en) 2013-05-22 2014-11-27 Wisconsin Alumni Research Foundation Rna-directed dna cleavage and gene editing by cas9 enzyme from neisseria meningitidis
US11685935B2 (en) 2013-05-29 2023-06-27 Cellectis Compact scaffold of Cas9 in the type II CRISPR system
WO2014198911A1 (en) 2013-06-14 2014-12-18 Cellectis Improved polynucleotide sequences encoding tale repeats
WO2014204725A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
CA2933134A1 (en) 2013-12-13 2015-06-18 Cellectis Cas9 nuclease platform for microalgae genome engineering

Similar Documents

Publication Publication Date Title
JP2016528894A5 (ja)
RU2019114217A (ru) Геномная инженерия
RU2016104056A (ru) Мультиплексная геномная инженерия, направляемая рнк
Song et al. Efficient genome editing using tRNA promoter-driven CRISPR/Cas9 gRNA in Aspergillus niger
Shi et al. CRISPR/Cas9-based genome editing of the filamentous fungi: the state of the art
Tröder et al. An optimized electroporation approach for efficient CRISPR/Cas9 genome editing in murine zygotes
Chen et al. Highly efficient mouse genome editing by CRISPR ribonucleoprotein electroporation of zygotes
EA201991441A1 (ru) ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9
Niu et al. Transformation of diatom Phaeodactylum tricornutum by electroporation and establishment of inducible selection marker
JP2018508198A5 (ja)
MX2018013256A (es) Metodos mejorados para la modificacion de acido nucleicos diana.
MX2019012772A (es) Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn.
JP2016027807A5 (ja)
JP2019508051A5 (ja)
EP4170029A3 (en) Modifying the specifity of plant non-coding rna molecules for silencing gene expression
JP2016537982A5 (ja)
RU2015129018A (ru) Рнк-направляемая инженерия генома человека
JP2016502840A5 (ja)
MX2016007654A (es) Metodos y composiciones para la modificacion dirigida de un genoma.
JP2010500029A5 (ja)
JP2012130346A5 (ja)
JP2016512691A5 (ja)
RU2014127702A (ru) Модифицированные Cascade-рибонуклеопротеины и их применения
WO2014039692A3 (en) Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
BR112012014080A2 (pt) método para modificação do material genético, método para geração de um ácido nucleico, monômero de endonuclease efetora tal, método para geração de um aninal, método para geração de uma planta, método para recombinação genética direcionada, ácido nucleico, cassete de expressão e célula hospedeira